Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antispike is an egg-derived polyclonal antibody (IgY) product developed by UNITEHPROM (a division of Belarusian State University) for the prevention and auxiliary management of COVID-19. The product is generated by immunizing hens with the SARS-CoV-2 spike protein, which induces the production of specific antibodies that are subsequently extracted and concentrated from the egg yolks. These IgY antibodies are designed to bind to the spike protein of the SARS-CoV-2 virus, neutralizing its ability to interact with human ACE2 receptors and thereby inhibiting viral entry into host cells. In Belarus, Antispike has been commercialized as a specialized food product or biologically active additive (supplement) intended to provide passive mucosal immunity and support the immune system against coronavirus infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antispike (Unitehprom BSU).